Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12475998 | 0.85 | TSHR (0.54) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2667226 | 0.84 | L3MBTL1 (0.50) | RAB9ANPC1SMN1; SMN2TP53POLB | |
| SCHEMBL3779190 | 0.83 | MAPK1 (0.48) | MAPTLMNARAB9AMAPK1NPC1 | |
| SCHEMBL11972293 | 0.83 | GAA (0.40) | MAPTLMNACYP3A4KCNH2MAPK1 | |
| SCHEMBL9071150 | 0.82 | ATM (0.47) | MAPTCYP3A4KCNH2MAPK1ALDH1A1 | |
| SCHEMBL9071240 | 0.82 | ALDH1A1 (0.39) | MAPTCA1CA2LMNACYP3A4 | |
| SCHEMBL11972292 | 0.80 | TP53 (0.44) | MAPTLMNARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL623312 | 0.80 | GCK (0.38) | MAPTLMNACYP3A4KCNH2MAPK1 | |
| SCHEMBL185193 | 0.80 | ALDH1A1 (0.48) | LMNACYP3A4RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11972318 | 0.79 | ILK (0.38) | MAPTCYP3A4KCNH2GLAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402327-B1 | Acetamide compounds as glucokinase activators, their process and medicinal applications | IMPETIS BIOSCIENCES LTD (IN) | 2018-03-07 | — | — | EP | disclosed |
| EP-2402327-B1 | Acetamide compounds as glucokinase activators, their process and medicinal applications | IMPETIS BIOSCIENCES LTD (IN) | 2018-03-07 | — | — | EP | disclosed |
| US-8921576-B2 | Spiroindoline compound, and medicinal agent comprising same | KOWA COMPANY, LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140309207-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | KOWA COMPANY, LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| EP-2781521-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-8501955-B2 | Acetamide derivatives as glucokinase activators, their process and medicinal application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2013-08-06 | — | — | US | disclosed |
| US-8222285-B2 | 1,3-dihydroxy substituted phenylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222285-B2 | 1,3-dihydroxy substituted phenylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-7888504-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100179121-A1 | 1,3-DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2010-07-15 | — | — | US | disclosed |
| US-20100179121-A1 | 1,3-DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2010-07-15 | — | — | US | disclosed |
| WO-2008154563-A1 | 1, 3 - DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080021052-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-24 | — | — | US | disclosed |
| US-20080021052-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-24 | — | — | US | disclosed |
| WO-2008005914-A2 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | GCK, GCKR, ALDOA | MAPT 319/4885CA1 1508/4885CA2 378/4885 |
| US-20080021052-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, NR4A3 | MAPT 4874/4885CA1 4132/4885CA2 3121/4885 |
| US-20140309207-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | GCKR, GCK, GALK1 | MAPT 4691/4885CA1 1755/4885CA2 767/4885 |
| US-20100179121-A1 | 1,3-DIHYDROXY SUBSTITUTED PHENYLAMIDE GLUCOKINASE ACTIVATORS | GCKR, GCK, NR4A3 | MAPT 4841/4885CA1 4273/4885CA2 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.